THROMBOCYTOPENIA AS ONE OF THE REASONS OF PROLONGED STAY IN THE NEONATAL INTENSIVE CARE UNIT

• Main Authors: Zulic Evlijana, Hadzic Devleta
• Format: Article
• Language: English
• Published: Association of medical doctors Sanamed Novi Pazar 2019-12-01
• Series: Sanamed
• Subjects: thrombocytopenia; newborn; sepsis; neonatal intensive care unit
• Online Access: http://www.sanamed.rs/OJS/index.php/Sanamed/article/view/352/180

The aim of this paper was to present the occurrence and severity of thrombocytopenia, with intracranial and another bleeding in neonates with sepsis, analyze the risk factors for the development of thrombocytopenia and compare it with the length of hospitalization in the Neonatal Intensive Care Unit (NICU). Thrombocytopenia is a platelet count <150x109 / L and is common in newborns during hospitalization in the NICU. In the early days of life, the most common causes of thrombocytopenia in newborns are conditions that lead to fetal hypoxia, intrauterine growth failure, maternal hypertension, and sepsis. In this study were included all newborns with thrombocytopenia, who were hospitalized in NICU, Children's Disease Clinic, University Clinical Centre in Tuzla, from 01.01.2014 to 01.01.2019. In our results, 379 newborns had severe, 337 moderate, and 127 milder forms of thrombocytopenia, without a statistically significant difference in the incidence of thrombocytopenia between groups of neonates born <37 GW and ≥ 37 GW. Sepsis was the most common cause of thrombocytopenia, 300 children had early sepsis and 190 late. We found the statistically significant difference in intracranial hemorrhage of the second degree and pulmonary hemorrhage among neonates born <37 GW in relation to newborns born ≥ 37GW. A statistically significant effect of length of stay of our neonates in the Department of Neonatal Intensive Therapy and morbidity was shown in relation to the lower gestational age and lower platelet counts. Conclusion: Timely diagnosis of the cause and development of thrombocytopenia with adequate and effective treatment can reduce the mortality and morbidity of newborns with perinatal risk for neonatal thrombocytopenia.